Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
25. januar 2019 oppdatert av: GlaxoSmithKline
Burden of Disease Among Patients With Eosinophilic COPD in Spain: Multicentre Observational Study
This observational study is designed to more specifically describe the burden of the disease and the use of healthcare resources of subjects with eosinophilic COPD that may be eligible in the future for a biologic treatment.
Subjects who attend a routine follow-up visit and fulfill the inclusion/exclusion criteria defined provide a signed informed consent will be invited by the investigator to participate in this study.
Subjects will be recruited in hospital Pulmonology Services across Spain.
It is planned to include approximately 20 centers.
To select the final participating centers, a feasibility study has been carried out in approximately 50 potential participating centers.
It has been estimated that each investigator will include 18 subjects during the 4-month inclusion period.
Total 354 subjects will be required: 250 subjects with an eosinophil level >=150 cells per microliter and 104 subjects with an eosinophil level <150 cells per microliter.
The study inclusion period will be 4 months (expected to be from November 2017 to March 2018) and the retrospective data collection period will be 12 months prior to the inclusion visit.
Studieoversikt
Status
Fullført
Forhold
Studietype
Observasjonsmessig
Registrering (Faktiske)
341
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Barcelona, Spania, 08036
- GSK Investigational Site
-
Madrid, Spania, 28040
- GSK Investigational Site
-
Madrid, Spania, 28046
- GSK Investigational Site
-
Valencia, Spania, 46017
- GSK Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
40 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Subjects who attend a routine follow-up visit and who fulfill inclusion/exclusion criteria will be invited by the investigator to participate in the study.
The study inclusion period will be four months (from November 2017 to March 2018) and the retrospective data collection period will be 12 months prior to the inclusion visit.
Beskrivelse
Inclusion Criteria:
- Subjects of both sexes aged >=40 years.
- Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record.
- Subjects with a history of smoking (current or past) >=10 pack-years.
- Subjects who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit. If the subject has several eosinophil test recorded in this period, the one closest to the inclusion visit determined in the stable phase should be selected; if it is not available, the record closest to the inclusion visit will be selected, even if it has been determined during an exacerbation. If no records are available, the subject will be invited to perform the test at the inclusion visit.
- Subjects currently exposed to inhaled triple maintenance therapy, defined as at least one overlapping prescription of an ICS with a LABA and with a LAMA in 2 or 3 inhaler devices, without more than 30 days of separation between prescriptions.
- Subjects who have experienced >=2 moderate exacerbations or >=1 severe exacerbation in the 12 months prior to the inclusion visit. Moderate exacerbation is defined as an exacerbation requiring antibiotics and/or oral corticosteroids or requiring an emergency visit <24 hours (without hospitalization). Severe exacerbation is defined as an exacerbation requiring hospitalization.
- Subjects who consent to participate in the study by signing the subjects written informed consent form.
Exclusion Criteria:
- Subjects without a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit and who refuse to perform the test during the inclusion visit.
- Subjects treated with oral corticosteroids continuously during the 12 months prior to the inclusion visit.
- Subjects with a diagnosis of Churg-Strauss disease, hypereosinophilic syndrome, allergic bronchopulmonary aspergillosis or other conditions that result in increased eosinophil levels independently of COPD.
- Subjects with oncologic disease undergoing treatment or with advanced oncologic disease (without possibility of remission), terminal subjects and/or subjects receiving palliative care.
- Cognitively impaired subjects who are not able to understand or complete the informed consent and HRQoL questionnaires.
- Subjects who have participated in an interventional clinical trial during the 12 months prior to the inclusion visit.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Subjects with COPD
Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of subjects requiring COPD maintenance treatment and rescue medication
Tidsramme: 12 months prior to the inclusion visit
|
Subjects currently exposed to inhaled triple maintenance therapy, defined as at least one overlapping prescription of an inhaled corticosteroid (ICS) with a long-acting beta2-agonist (LABA) and with a long-acting muscarinic antagonist (LAMA) in 2 or 3 inhaler devices, without more than 30 days of separation between prescriptions along with rescue medication use will be analyzed.
|
12 months prior to the inclusion visit
|
|
Number of subjects with moderate and severe exacerbations
Tidsramme: 12 months prior to the inclusion visit
|
Subjects who have experienced >=2 moderate exacerbations or >=1 severe exacerbation in the 12 months prior to the inclusion visit.
Moderate exacerbation is defined as an exacerbation requiring antibiotics and/or oral corticosteroids or requiring an emergency visit <24 hours (without hospitalization).
Severe exacerbation is defined as an exacerbation requiring hospitalization.
|
12 months prior to the inclusion visit
|
|
Number of subjects with COPD-related scheduled and unscheduled primary and secondary care visits
Tidsramme: 12 months prior to the inclusion visit
|
Subjects with COPD-related scheduled and unscheduled primary and secondary care visits will be analyzed.
|
12 months prior to the inclusion visit
|
|
Number of subjects with COPD-related emergency visits to primary care and hospital
Tidsramme: 12 months prior to the inclusion visit
|
Subjects with COPD-related emergency visits to primary care and hospital will be analyzed.
|
12 months prior to the inclusion visit
|
|
Number of subjects with COPD-related hospitalizations
Tidsramme: 12 months prior to the inclusion visit
|
Subjects with COPD-related hospitalizations will be analyzed.
|
12 months prior to the inclusion visit
|
|
Number of days of hospitalizations
Tidsramme: 12 months prior to the inclusion visit
|
The number of days of hospitalization for subjects will be analyzed.
|
12 months prior to the inclusion visit
|
|
Number of subjects with COPD-related complementary tests
Tidsramme: 12 months prior to the inclusion visit
|
Subjects with COPD-related complementary tests will be analyzed.
|
12 months prior to the inclusion visit
|
|
Number of subjects with COPD-related days-off work
Tidsramme: 12 months prior to the inclusion visit
|
Subjects with COPD-related days-off work will be analyzed.
|
12 months prior to the inclusion visit
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Subjects age as a measure of sociodemographic characteristics
Tidsramme: 4 months (inclusion period)
|
Age will be recorded for descriptive analysis of the sociodemographic characteristics of the subjects participating in the study.
A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.
|
4 months (inclusion period)
|
|
Number of subjects with different gender
Tidsramme: 4 months (inclusion period)
|
Gender will be recorded for descriptive analysis of the sociodemographic characteristics of the subjects participating in the study.
A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.
|
4 months (inclusion period)
|
|
Number of subjects with different sociodemographic variables
Tidsramme: 4 months (inclusion period)
|
Subjects with different educational level, employment status, monthly net income will be recorded for descriptive analysis of the sociodemographic characteristics of the subjects participating in the study A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.
|
4 months (inclusion period)
|
|
Number of subjects with abnormal clinical variables
Tidsramme: 4 months (inclusion period)
|
Clinical variables comprising weight, height, body mass index (self-calculated), smoking history, Charlson comorbidity index, diagnosis of asthma will be assessed for abnormalities.
A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.
|
4 months (inclusion period)
|
|
Number of subjects with abnormal COPD related variables
Tidsramme: 12 months prior to the inclusion visit
|
COPD variables comprising COPD diagnosis date, pulmonary function with bronchodilator test, modified Medical Research Council (mMRC) dyspnea scale, clinical phenotypes according to Spanish COPD Clinical Guidelines (GesEPOC) criteria will be assessed for abnormalities.
A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.
|
12 months prior to the inclusion visit
|
|
Number of subjects with abnormal blood cell count
Tidsramme: 12 months prior to the inclusion visit
|
Peripheral blood eosinophil count, peripheral blood neutrophil count, peripheral blood leukocyte count, fibrinogen and red cell distribution width will be assessed for abnormalities.
|
12 months prior to the inclusion visit
|
|
COPD Assessment Test (CAT) score as a measure of Health Related Quality of Life (HRQoL)
Tidsramme: 4 months (inclusion period)
|
The CAT questionnaire is a COPD-specific questionnaire that measures the impact of the disease on HRQoL and allows symptoms to be described.
It consists of 8 items, which yield a score range from 0 to 40, 0 representing the lowest impact on HRQoL and 40 the maximum impact.
|
4 months (inclusion period)
|
|
EuroQOL five dimensions five level (EQ-5D-5L) score as a measure of HRQoL
Tidsramme: 4 months (inclusion period)
|
The EQ-5D-5L is a preference-based generic HRQoL questionnaire, consisting on five health dimensions (mobility, personal care, daily activities, pain/discomfort and anxiety/depression), divided in five levels of severity (no problems, slight problems, moderate problems, severe problems and extreme problems).
It included also a visual analogue scale (VAS) in which respondents are asked to evaluate their overall health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).
|
4 months (inclusion period)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
5. desember 2017
Primær fullføring (Faktiske)
31. oktober 2018
Studiet fullført (Faktiske)
10. desember 2018
Datoer for studieregistrering
Først innsendt
12. februar 2018
Først innsendt som oppfylte QC-kriteriene
12. februar 2018
Først lagt ut (Faktiske)
19. februar 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
29. januar 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. januar 2019
Sist bekreftet
1. januar 2019
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 206555
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .